Huntington's Disease study: ALN-HTT02
Official title A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
ClinicalTrials.gov ID: NCT06585449
What this study is testing
What is ALN-HTT02?
This is an investigational medicine being studied as a potential treatment for Huntington's Disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether ALN-HTT02 is safe and how it behaves in the body.
- Who it's for
- You may be able to join if you are an adult with Huntington's disease.
- What's involved
- You will receive the drug and have blood tests and health checks. The team will monitor you closely.
- Time commitment
- The study lasts a few weeks, with several clinic visits for dosing and monitoring.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 25 to 70
You may be able to join if
- Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS)
You likely can't join if
- Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening
- Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies
- Has alanine aminotransferase or aspartate aminotransferase \>2× upper limit of normal (ULN)
- Has an estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2 at screening
- Has received an investigational agent within the last 1 year or 5 half-lives (if known) Note: other protocol defined inclusion / exclusion criteria...
The study team makes the final eligibility decision.
Where it is enrolling
- Edmonton, Canada
- Montreal, Canada
- Ottawa, Canada
- Vancouver, Canada
- Berlin, Germany
- Bochum, Germany
- Bonn, Germany
- Dresden, Germany
- Münster, Germany
- Taufkirchen, Germany
- Ulm, Germany
- Birmingham, United Kingdom
- Cambridge, United Kingdom
- Cardiff, United Kingdom
- Glasgow, United Kingdom
- Greater Manchester, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
- Plymouth, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 25 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Edmonton, Canada; Montreal, Canada; Ottawa, Canada; Vancouver, Canada; Berlin, Germany; Bochum, Germany and 13 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.